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Enhanced safety surveillance (ESS) was conducted 
in the United Kingdom and Finland for Vaxigrip and 
Intanza 15 µg to comply with the European Medicines 
Agency interim guidance aimed to detect any poten-
tial increase in reactogenicity in near real time follow-
ing the annual update of the influenza vaccine strain 
composition. This pilot passive ESS was established 
to strengthen safety monitoring by facilitating sponta-
neous vaccinee reports and estimating near real-time 
vaccinee exposure. The primary objective was to esti-
mate the reporting rates of suspected adverse reac-
tions (ARs) occurring within 7 days post vaccination 
during the northern hemisphere 2015/16 influenza 
season. Among the Vaxigrip vaccinees (n = 1,012), 32 
(3.2%) reported a total of 122 suspected ARs, includ-
ing 110 suspected ARs that occurred within 7 days 
post vaccination. Among the Intanza 15 µg vaccinees 
(n = 1,017), 31 (3.0%) reported a total of 114 suspected 
ARs, including 99 that occurred within 7 days post-
vaccination. These results were consistent with the 
known safety profile of the two vaccines and did not 
show any change in reactogenicity or safety concerns. 
This passive ESS showed improved data reporting 
and demonstrated its suitability to health authorities’ 
requirements; further fine tuning of the methodology 
is under discussion between all stakeholders.
Introduction
Influenza is an acute viral respiratory infection that 
affects 5% to 20% of the global population annually 
[1]. This rate amounts to ca 25 to 100 million persons 
each influenza season in Europe. The epidemiology of 
seasonal influenza has been well characterised, par-
ticularly in the northern hemisphere (NH), where the 
influenza season typically falls between November and 
April [2].
Vaccination is the only preventive measure for sea-
sonal influenza. As recommended by the World Health 
Organization (WHO), the current trivalent or quadriva-
lent marketed influenza vaccines are composed of 
antigens from two influenza A strains and one or two 
influenza B virus strain [1]. The recommendation is 
based on extensive surveillance of influenza strains 
through the WHO Global Influenza Surveillance net-
work as the influenza strains continue to evolve, caus-
ing an antigenic mismatch between the virus strains in 
the vaccine and the circulating viruses in the subse-
quent influenza season [3,4]. Consequently, the strain 
composition of the influenza vaccine is adapted to the 
epidemiological situation to provide optimal protection 
for the population.
The European Medicines Agency (EMA) requests annual 
enhanced safety surveillance (ESS) for all seasonal 
influenza vaccines. The purpose of this requirement is 
to rapidly detect a clinically significant change (beyond 
what was known or expected with the previous vaccine 
composition) in the frequency and/or severity of reac-
togenicity (local, systemic or allergic reactions) that 
may indicate the potential for more serious risks as 
exposure to the vaccine increases. To avoid false attri-
bution of such a signal to the general intrinsic safety 
profile of a product, it is recommended that ESS should 
involve subanalysis of more than one batch [5].
Interim guidance was issued by the Pharmacovigilance 
Risk Assessment Committee (PRAC) in April 2014 to 
outline the principles to be followed for improved 
continuous routine surveillance of influenza vaccines 
[5]. Experiences and limitations faced during the NH 
2014/15 pilot influenza season were discussed between 
the vaccine marketing authorisation holders (MAHs) 
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through a dedicated safety task force within Vaccines 
Europe (European Vaccines Manufacturers Association 
within the European Federation of Pharmaceutical 
Industries and Associations (EFPIA)) and were pre-
sented to the EMA/PRAC/Vaccine Working Party in 
November 2014. By December 2014, the PRAC recom-
mended establishing a passive ESS for the NH 2015/16 
influenza season to the MAHs. Thus, a new design 
was developed to monitor Vaxigrip (intramuscular tri-
valent split-virion inactivated influenza vaccine) and 
Intanza 15 µg (intradermal trivalent split-virion inacti-
vated influenza vaccine) reactogenicity that relied on 
enhanced routine pharmacovigilance early in the influ-
enza season.
In the United Kingdom (UK), Vaxigrip is recommended 
for adults older than 65 years, risk groups between 18 
and 64 years and children between 6 months and 2 
years of age. In Finland, Vaxigrip is recommended to 
be used in children 6 months to 2 years of age and in 
at-risk groups from 3 to 18 years of age. Children aged 
2 to 3 years in Finland and 2 years and older in the UK 
preferentially receive another influenza vaccine (live 
attenuated influenza vaccine) per respective national 
recommendations [6,7]. Intanza 15 µg is only used in 
the UK and recommended for individuals 60 years and 
older. Notably, the Vaxigrip trade name in the UK is 
Inactivated Influenza (split virion) BP vaccine, but it 
will be referred to as Vaxigrip in this manuscript.
The principle of this passive ESS was to rapidly esti-
mate vaccine usage or coverage (number of vaccinees 
or doses administered) and to facilitate passive report-
ing of suspected adverse reactions (ARs) from vac-
cinees in order to derive AR reporting rates from the 
same source of population. For these spontaneous 
reports, causality assessment was not requested from 
the vaccinee or healthcare professionals (HCPs) and 
was not performed by the MAH.
The primary objective was to estimate the reporting 
rates of suspected ARs occurring within 7 days follow-
ing routine vaccination with Vaxigrip or Intanza 15 µg 
during the NH 2015/16 influenza season. The second-
ary objectives were to estimate the reporting rates of 
suspected ARs occurring within 7 days following rou-
tine vaccination with Vaxigrip or Intanza 15 µg accord-
ing to age group and of serious suspected ARs post 
vaccination not limited to 7 days. This ESS also aimed 
to provide reference reporting rates for comparison in 
the next influenza season (2016/17). As an exploratory 
objective, a batch analysis would be performed if a 
signal was detected, whenever possible, to avoid false 
attribution of the signal to the general intrinsic safety 
profile of the product.
Methods
Design
This was a multicentre, non-interventional, observa-
tional, passive ESS conducted in the UK and Finland 
to ensure the representativeness of all age groups 
indicated for each vaccine and the use of at least two 
different batches. The passive ESS relied on enhanced 
(facilitated) reporting of suspected ARs by increasing 
the awareness of vaccinees, through trained HCPs, 
regarding the importance of reporting suspected ARs 
post vaccination (especially those occurring within 
7 days post vaccination) and by distributing safety 
report cards (SRCs) that allowed vaccinees to report 
suspected ARs through a dedicated toll-free telephone 
number. Near real-time, age-specific, brand-specific 
influenza vaccination coverage was achieved in addi-
tion to near real-time analysis estimating suspected AR 
reporting rates within 7 days post vaccination during 
the NH 2015/16 influenza season.
Setting
The passive ESS started on 13 October 2015 for Vaxigrip 
and 17 October 2015 for Intanza 15 µg and ended when 
1,000 SRCs each had been distributed (on 2 December 
2015 for Vaxigrip and on 8 December 2015 for Intanza 
15 µg). Any reports received outside the ESS period 
were handled as routine spontaneous reports but were 
not included in the analysis.
Participants
Vaccinees who received Vaxigrip or Intanza 15 µg in 
routine practice during the NH 2015/16 influenza sea-
son and who accepted the SRC (or their parents, in 
cases of child vaccinees) were eligible for participation 
in this ESS. There were no exclusion criteria.
Procedures and data collection method
A paper SRC specific to Vaxigrip or Intanza 15 µg pro-
vided the following information to the vaccinee: details 
regarding the ESS, instructions on how to report sus-
pected ARs, the dedicated local toll-free telephone 
number, the site identifier, a unique SRC identification 
number, vaccine brand and batch, vaccination date and 
name of the treating physician.
Table 1
Safety report cards distributed for Vaxigrip and Intanza 
15 µg vaccinees, by age group, United Kingdom and 
Finland, 2015/16 (n = 2,029)
Age group
Safety report cards distributed
Number Percentage
Vaxigrip 
6 months to < 6 years 496 49.0
≥ 6 to < 13 years 111 11.0
≥ 13 to < 18 years 19 1.9
≥ 18 to ≤ 65 years 149 14.7
> 65 years 237 23.4
Total Vaxigrip 1,012 100.0
Intanzaa 
Total Intanza 1,017 100.0
a All Intanza 15 µg vaccinees were ≥ 60 years-old.
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Vaccine coverage data were collected at practice level 
by the HCP/vaccinator(s) on a real-time basis (at least 
once a day) using an electronic data capture system. 
Vaccinees were encouraged to report any suspected 
post-vaccination ARs, especially those occurring within 
7 days (although reports of ARs after 7 days were also 
considered for the analysis). A structured telephone 
interview was developed to ensure the appropriate-
ness and completeness of data collection when vac-
cinees called to report suspected ARs.
All events reported spontaneously by vaccinees were 
considered suspected ARs and were recorded and 
reported according to Good Pharmacovigilance Practice 
module VI [8]. All suspected ARs were described. PRAC 
Adverse Events of Interest (AEIs), as listed in the guid-
ance, were also specifically described [5]. Per protocol, 
side effects reported by a vaccinee or HCP were consid-
ered suspected ARs (unless the reporters specifically 
stated the events to be unrelated or excluded a causal 
relationship).
Safety signals were defined per Good Pharmacovigilance 
Practice Annex I revision 3 [9].
Table 2
Summary of suspected adverse reactions by age group, time of onset and brand, United Kingdom and Finland, 2015/16 
(n = 2,029)
Time of onset after vaccination
≤ 7 days > 7 days Totala
   n       %       n       %       n       %   
Vaxigrip (n = 1,012) 
Total number of suspected AR 110 10.9 12 1.2 122 12.1
Total number of PRAC AEI 42 4.1 4 0.4 46 4.5
Total number of vaccinees with at least 1 suspected AR 31 3.1 3 0.3 32 3.2
Total number of vaccinees with PRAC AEI 22 2.2 3 0.3 25 2.5
6 months to < 6 years (n = 496) 
Number of suspected AR 40 8.1 2 0.4 42 8.5
Number of PRAC AEI 20 4.0 1 0.2 21 4.2
Number of vaccinees with at least 1 suspected AR 14 2.8 1 0.2 14 2.8
Number of vaccinees with PRAC AEI 11 2.2 1 0.2 12 2.4
 ≥ 6 to < 13 years (n = 111)
Number of suspected AR 8 7.2 0 0 8 7.2
Number of PRAC AEI 7 6.3 0 0 7 6.3
Number of vaccinees with at least 1 suspected AR 2 1.8 0 0 2 1.8
Number of vaccinees with PRAC AEI 2 1.8 0 0 2 1.8
 ≥ 13 to < 18 years (n = 19)
No data reported for this age group
 ≥ 18 to ≤ 65 years (n = 149)
Number of suspected AR 12 8.0 0 0 12 8.0
Number of PRAC AEI 4 2.7 0 0 4 2.7
Number of vaccinees with at least 1 suspected AR 4 2.7 0 0 4 2.7
Number of vaccinees with PRAC AEI 2 1.3 0 0 2 1.3
 > 65 years (n = 237)
Number of suspected AR 50 21.1 10 4.2 60 25.3
Number of PRAC AEI 11 4.6 3 1.3 14 5.9
Number of vaccinees with at least 1 suspected AR 11 4.6 2 0.8 12 5.1
Number of vaccinees with PRAC AEI 7 3.0 2 0.8 9 3.8
Intanzab (n = 1,017) 
Total number of suspected AR 99 9.7 15 1.5 114 11.2
Total number of PRAC AEI 53 5.2 3 0.3 56 5.5
Total number of vaccinees with at least 1 suspected AR 29 2.9 3 0.3 31 3.0
Total number of vaccinees with PRAC AEI 26 2.6 3 0.3 28 2.8
AEI: adverse event of interest; AR: adverse reaction; PRAC: pharmacovigilance risk assessment committee.
a Not all numbers add up as vaccinees could report suspected AR in both time intervals.
b All Intanza 15 µg vaccinees were ≥ 60 years-old.
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Population size
The number of SRCs needed to be distributed per brand 
(n = 1,000) was estimated based on the expected AR 
reporting rate and the ability to detect common or very 
common ARs. The number of sites (six in Finland and 
14 in the UK) was based on the expected volume of 
vaccinations with Vaxigrip and Intanza 15 µg and their 
ability to distribute SRCs within a short time period. 
Age representativeness of the population was ensured 
through country/site selection (in Finland, only paedi-
atric vaccination centres were selected); nevertheless, 
the SRC distribution at site level followed routine vac-
cination practices. The number of vaccinees who would 
potentially report suspected ARs could only be stimu-
lated but not controlled.
Statistical analysis
The ESS population included all vaccinees who were 
vaccinated in routine practice with either Vaxigrip or 
Intanza 15 µg and who received the SRC. No confirma-
tory hypothesis testing was conducted for the analy-
ses. All analyses were descriptive and were produced 
using SAS version 9.2. Verbatim ARs were coded with 
Medical Dictionary for Regulatory Activities terminology 
(version 18.0) and processed according to routine phar-
macovigilance processes.
ESS reporting rates were calculated per brand using 
the following formula:
ESS reporting rate = (Number of vaccinees report-
ing ARs within 7 days x 100) / total number of SRCs 
distributed
Suspected AR reporting rates were estimated per brand 
using the following method:
Suspected AR reporting rate = (Number of ARs within 7 
days x 100) / total number of SRCs distributed
Confidence intervals (CIs) for ESS reporting rates were 
computed using the Wald method if the AR count 
was ≥ 5 and using exact method if the AR count was < 5.
All suspected ARs (including PRAC AEIs, serious sus-
pected ARs and other suspected ARs) and correspond-
ing AR reporting rates were reported and summarised 
by vaccine, age groups (Vaxigrip: 6 months to < 6 years; 
Table 3
Most frequently reported suspected adverse reactions (with reporting rates  ≥ 1% ) by age group and time of onset, United 
Kingdom and Finland, 2015/16 (n = 2,029)
Preferred term
Time of onset
≤ 7 days > 7 days Total
n % CI n % CI n % CI
Vaxigrip (n = 1,012) 
6 months to < 6 years (n = 496) 
Cough 5 1.0 0.1–1.9 0 5 1.0 0.1–1.9
Pyrexia 7 1.4 0.4–2.4 1 0.2 0.0–1.1 8 1.6 0.5–2.7
Rhinorrhoea 5 1.0 0.1–1.9 1 0.2 0.0–1.1 6 1.2 0.2–2.2
 ≥ 6 to < 13 years (n = 111)
Vaccination site erythema 2 1.8 0.2–6.4 0 2 1.8 0.2–6.4
 ≥ 13 to < 18 years (n = 19)
No data reported for this group
 ≥ 18 to ≤ 65 years (n = 149)
No suspected AR ≥ 1% of total reported for this group
 > 65 years (n = 237)
Cough 3 1.3 0.3–3.7 1 0.4 0.0–2.3 4 1.7 0.5–4.3
Fatigue 2 0.8 0.1–3.0 1 0.4 0.0–2.3 3 1.3 0.3–3.7
Headache 3 1.3 0.3–3.7 1 0.4 0.0–2.3 4 1.7 0.5–4.3
Influenza-like illness 5 2.1 0.3–3.9 0 5 2.1 0.3–3.9
Malaise 3 1.3 0.3–3.7 2 0.8 0.1–3.0 5 2.1 0.3–3.9
Nasopharyngitis 3 1.3 0.3–3.7 0 3 1.3 0.3–3.7
Oropharyngeal pain 2 0.8 0.1–3.0 1 0.4 0.0–2.3 3 1.3 0.3-3.7
Intanza b 15 µg (n = 1,017) 
Vaccination site pain 10 1.0 0.4–1.6 0 10 1.0 0.4-1.6
AR: adverse reaction; CI: confidence interval.
a Not all numbers add up as vaccinees could report suspected AR in both time intervals.
b All Intanza 15 µg vaccinees were ≥ 60 years-old.
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≥ 6 years to < 13 years; ≥ 13 years to < 18 years, ≥ 18 
years to ≤ 65 years, and > 65 years; Intanza 15 µg: ≥ 60 
years), seriousness (Yes/No), severity (Grade 1 (mild), 
Grade 2 (moderate), Grade 3 (severe), and unknown 
per protocol severity definition), and day of onset since 
vaccination (≤ 7 and > 7 days). A similar analysis was 
also performed on serious suspected ARs.
The mean number of ARs per vaccinee who reported at 
least one suspected AR was also calculated. For each 
brand, weekly reports for signal detection were gener-
ated and analysed. A 1-month interim report (1 month 
after the first SRCs were distributed) and a final report 
were compiled and submitted to the relevant health 
authorities. AR reporting rates were calculated and 
compared with the frequency of the AEIs reported dur-
ing the NH 2014/15 influenza season clinical trials and 
with the expected rates based on current product-spe-
cific data from the Summary of Product Characteristics 
(SmPC) [10]. No statistical tests were performed [11].
Ethics
The ESS was conducted in accordance with 
Good Epidemiological Practice, the European 
Network of Centres for Pharmacoepidemiology 
and Pharmacovigilance Guide on Methodological 
Standards in Pharmacoepidemiology [12,13] and Good 
Pharmacovigilance Practices [8]. The ESS was submit-
ted to national authorities as required by the local 
regulations and was approved by national ethics 
committees.
Results
Exposure data
A total of 1,012 SRCs for Vaxigrip and 1,017 SRCs for 
Intanza 15 µg were distributed to different age groups 
in the UK and Finland during the 8-week period from 13 
October to 8 December 2015 (Table 1). We also consid-
ered in the analysis additional SRCs distributed on the 
same day the 1,000th SRC was reached. 
The ESS covered 21 different batches of Vaxigrip and 
three different batches of Intanza 15 µg. Approximately 
half (51%) of the Vaxigrip vaccinees received the same 
batch; the other half (49%) received Vaxigrip from 20 
different batches. Almost all of the Intanza vaccinees 
(except three vaccinees) received the same batch. 
Because no safety signal was detected for either 
Vaxigrip or Intanza 15 µg, no specific batch analysis 
was conducted.
Vaxigrip safety data
Among the Vaxigrip vaccinees, 32 (3.2%) reported a 
total of 122 suspected ARs (mean of 3.8 ARs/vaccinee 
who reported at least one AR), including 110 suspected 
ARs that occurred within 7 days post-vaccination (Table 
2).
The highest reporting rate of suspected ARs occur-
ring within 7 days post vaccination was observed in 
vaccinees older than 65 years; 11 of these vaccinees 
reported 50 suspected ARs (4.5 ARs within 7 days/vac-
cinee who reported at least one AR; Table 2).
Table 4
Most frequently reported PRAC adverse events of interest (events reported at least twice) with onset within 7 days, by 
severity, United Kingdom and Finland, 2015/16 (n = 2,029)
Preferred term Mild Moderate Severe Unknown Total
   n       %    95% CI    n       %    95% CI    n       %    95% CI    n       %    95% CI    n       %    95% CI
Vaxigrip (n = 1,012) 
Number of vaccinees with 
PRAC AEI 9 0.9 0.3–1.5 3 0.3 0.1–0.9 5 0.5 0.1–0.9 9 0.9 0.3–1.5 22 2.2 1.3–3.1
Headache 0 0 0 0 0 0 1 0.1 0.0–0.5 4 0.4 0.1–1.0 5 0.5 0.1–0.9
Pyrexia 3 0.3 0.1–0.9 1 0.1 0.0–0.5 2 0.2 0.0–0.7 3 0.3 0.1–0.9 9 0.9 0.3–1.5
Vaccination site erythema 1 0.1 0.0–0.5 1 0.1 0.0–0.5 2 0.2 0.0–0.7 1 0.1 0.0–0.5 5 0.5 0.1–0.9
Intanza 15 µg (n = 1,017) 
Number of vaccinees with 
PRAC AEI 18 1.8 1.0–2.6 2 0.2 0.0–0.7 3 0.3 0.1–0.9 7 0.7 0.2–1.2 26 2.6 1.6–3.5
Malaise 3 0.3 0.1–0.9 0 0 0 1 0.1 0.0–0.5 2 0.2 0.0–0.7 6 0.6 0.1–1.1
Vaccination site erythema 6 0.6 0.1–1.1 1 0.1 0.0–0.5 0 0 0 2 0.2 0.0–0.7 9 0.9 0.3–1.5
Vaccination site pain 9 0.9 0.3–1.5 0 0 0 0 0 0 1 0.1 0.0–0.5 10 1.0 0.4–1.6
Vaccination site pruritus 4 0.4 0.1–1.0 0 0 0 1 0.1 0.0–0.5 0 0 0 5 0.5 0.1–0.9
Vaccination site swelling 5 0.5 0.1–0.9 0 0 0 0 0 0 0 0 0 5 0.5 0.1–0.9
AEI: adverse event of interest; PRAC: pharmacovigilance risk assessment committee.
Note: PRAC AEIs as listed in the guidance were specifically described as follows: Injection site reactions (pain, erythema, pruritus, swelling, 
induration and ecchymosis) and systemic reactions (fever > 38 °C, headache, malaise, myalgia, shivering, rash, vomiting, nausea, arthralgia, 
decreased appetite, irritability (for vaccinees younger than 5 years), crying (for vaccinees younger than 5 years), and events indicative of 
allergic and hypersensitivity reactions including ocular symptoms). 
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There was no obvious distribution pattern in the type 
of suspected ARs across age groups, with the majority 
of individual ARs occurring at a frequency of less than 
1%. The total number of suspected ARs that occurred at 
a frequency of 1% or higher are presented by age group 
and time of onset in Table 3.
One serious suspected AR was reported following 
Vaxigrip vaccination. A person in their late 70s expe-
rienced a chest infection (lower respiratory tract infec-
tion, which was considered to be an important medical 
event) 18 days after vaccination, which started with 
sore throat, headache, coughing and feeling ‘unpleas-
ant’ and hot. The vaccinee’s medical history included a 
previous chest infection 2 weeks before the influenza 
vaccination. The vaccinee was later reported to be 
recovering from the second chest infection following 
vaccination.
Overall, 46 suspected PRAC AEIs were reported by 25 
vaccinees (1.8 suspected AEIs/vaccinee who reported 
at least one AR). Of these AEIs, 42 suspected AEIs 
occurred within 7 days post vaccination (Table 2). The 
most frequent (n ≥ 2) PRAC AEIs with an onset within 
7 days post vaccination are presented by severity in 
Table 4.
There was no obvious distribution pattern in the type 
of AEIs, their severity or their frequency observed 
across age groups for Vaxigrip. All AEIs were consid-
ered not serious.
Intanza safety data
Among the Intanza 15 µg vaccinees, 31 (3.0%) reported 
114 suspected ARs (3.7 ARs/vaccinee who reported 
at least one AR), including 99 suspected ARs that 
occurred within 7 days post vaccination (Table 2).
All of the suspected ARs were non-serious. One vac-
cinee could not be included in the analysis because 
of insufficient information to identify the SRC number. 
This vaccinee had reported the non-serious suspected 
ARs of cough and pain. The most frequently reported 
suspected ARs within 7 days post vaccination (those 
reported by ≥ 1% of vaccinees) are listed in Table 3.
Overall, 56 suspected PRAC AEIs were reported by 28 
vaccinees (2 AEIs/vaccinee who reported at least one 
AR). Of these AEIs, 53 AEIs occurred within 7 days post 
vaccination (Table 2). All AEIs were considered non-
serious. The most frequent (n ≥ 2) PRAC AEIs with an 
onset within 7 days post-vaccination are presented by 
severity in Table 4.
Comparison of the reported frequencies 
with the reference data from the northern 
hemisphere 2014/15 enhanced safety 
surveillance
No increase was noted in the observed AEI frequencies 
for Vaxigrip or Intanza 15 μg during the NH 2015/16 ESS 
when compared with the frequencies observed during 
the NH 2014/15 ESS (data not shown).
Comparison of the reported frequencies with 
the Summary of Product Characteristics
Vaxigrip
Influenza-like illness (ILI) was found to have a higher 
reporting frequency in this ESS compared with the 
Vaxigrip SmPC. ILI was reported by five vaccinees 
Table 5
Comparison of other reactions (not solicited in the northern hemisphere 2014/15 clinical trial) with the Vaxigrip Summary 
of Product Characteristics, United Kingdom and Finland, 2015/16 (n = 2,029)
Adverse reactiona
ESS 2015/16 
(≤ 7 days)
Vaxigrip SmPC 
(≤ 7 days) Frequency
b Comparison result
Age group
Observed 
frequency per age 
group
Age group SmPC ESS 2015/16 Higher or equal or lower than SmPC
Diarrhoea 6 months to < 6 years 0.2% 6 to 35 months Very common Uncommon Lower
Diarrhoea ≥ 18 yearsc 0.3% ≥ 18 years Uncommon Uncommon Equal
Dizziness ≥ 18 yearsc 0.5% ≥ 18 years Uncommon Uncommon Equal
Influenza- like illness ≥ 18 yearsc 1.3% ≥ 18 years Uncommon Common Higher
Asthenia ≥ 18 yearsc 0.3% ≥ 18 years Very common Uncommon Lower
Sweating increased ≥ 18 yearsc 0.3% ≥ 18 years Common Uncommon Lower
ESS: enhanced safety surveillance; SmPC: summary of product characteristics.
Note: A vaccinee with multiple occurrences of an adverse reaction is counted only once under the applicable system organ class/preferred 
term.
a Only not solicited adverse reactions in the northern hemisphere 2014/15 clinical trial and reported in this ESS are compared with the SmPC 
and included in this table.
b Very common (≥ 1/10 or ≥ 10%); common (≥ 1/100 to < 1/10 or ≥ 1% to < 10%); uncommon (≥ 1/1,000 to < 1/100 or ≥ 0.1% to < 1%); rare (≥ 1/10,000 
to < 1/1,000 or ≥ 0.01% to < 0.1%); very rare (< 1/10,000 or < 0.01%).
c Combined age groups of adult and elderly vaccinees.
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(2.1%; 95% CI: 0.3–3.9%) older than 65 years but was 
not reported by vaccinees aged 18–65 years, which led 
to a combined ILI reporting rate of 1.3%. This observed 
frequency was slightly higher than the ‘uncommon’ 
(≥ 0.1% to < 1%) frequency for ILI in the groups of adults 
and elderly people in the SmPC. However, the slightly 
higher reporting rate observed was not considered 
clinically relevant upon medical review. The other sus-
pected ARs had frequencies lower than or equal to the 
SmPC frequencies (Table 5).
Intanza 15 µg
Fatigue and sweating (hyperhydrosis) were reported 
following Intanza vaccination, and the reported fre-
quencies in the ESS were similar to those referenced in 
the SmPC (Table 6).
Discussion
In this ESS, vaccinees were encouraged to report any 
suspected ARs that they experienced, with an empha-
sis on those occurring within 7 days post vaccination. 
Hence, the reporting of suspected ARs was stimulated 
but remained spontaneous in nature (i.e. not solic-
ited). We observed higher reporting rates when spon-
taneous notification was stimulated (3.2% for Vaxigrip 
and 3.0% for Intanza 15 µg) compared with reporting 
rates in routine pharmacovigilance (passive spontane-
ous non-stimulated system). Spontaneous reporting 
rates after seasonal influenza vaccination range from 
20 to 90 reports per 1,000,000 people vaccinated [14-
19]. Passive ESS has been shown to increase reporting 
rates two- to fivefold when switched from routine phar-
macovigilance [20,21].
This study was executed in a time-efficient manner. 
Approximately 1.5–2 hours per HCP were dedicated to 
protocol training, processes to be used, management 
of vaccinees, site management and the end of the ESS 
process, depending on staff involved. The contact cen-
tre needed ca 15 min per vaccinee to record the sus-
pected AR. However, information on the time spent per 
vaccinee by the HCP to explain the ESS, distribute the 
SRCs, and explain how ARs were to be reported was 
not collected as part of this ESS.
The strengths of this ESS were that the number of SRCs 
distributed was consistent with the estimated sample 
size and that weekly analyses were performed, which 
allowed for near real-time investigation of the reac-
togenicity of Vaxigrip and Intanza 15 µg. The safety 
reports received were well documented in terms of 
exposure data (brand, batch and date of vaccination), 
which is not always the case with routine pharmacovig-
ilance. The overall reporting rates for the two products 
were of the same order of magnitude. By considering 
two countries and using a thorough site selection pro-
cess, we were able to gather data across all age groups 
as recommended by the guidance, including data in 
paediatric age groups, over-represented compared 
with paediatric routine coverage rate.
Overall, the mean numbers of suspected ARs per vac-
cinee who reported at least one AR within 7 days post-
vaccination were 3.8 for Vaxigrip and 3.7 for Intanza 15 
µg, ranging between 0 (for vaccinees in the 13–18 years 
age group owing to the small number of SRCs distrib-
uted) and 13 (for vaccinees older than 65 years). The 
higher average number of suspected ARs in the group 
of elderly people could be due to the well-known cor-
relation between increasing age and AR reporting rate. 
Frailty, medical history and concomitant use of medica-
tion are common causes of this phenomenon [22]. No 
obvious distribution pattern in the type and frequency 
of suspected ARs was observed across age groups for 
either vaccine.
All of the reported ARs were non-serious, except for 
one serious AR reported after Vaxigrip vaccination. The 
passive ESS results do not raise any concerns about 
the safety of Vaxigrip and Intanza 15 µg. None of the 
observed frequencies of AEIs in the current ESS were 
above the frequencies observed during the NH 2014/15 
Table 6
Comparison of other reactions (not solicited in the northern hemisphere 2014/15 clinical trial) with Intanza 15 µg summary 
of product characteristics, United Kingdom and Finland, 2015/16 (n = 2,029)
Adverse 
reaction
ESS 2015/16  
(≤ 7 days +  > 7 days)
Intanza 15 µg SmPC 
(≤ 7 days +  > 7 days) Frequency
b Comparison result
Age groupc Reported frequency per age group Age group SmPC ESS 2015/16
Higher or equal or lower 
than SmPC
Fatigue ≥ 18 years 0.2% > 60 years Uncommon Uncommon Equal
Sweating ≥ 18 years 0.2% > 60 years Uncommon Uncommon Equal
ESS: enhanced safety surveillance; SmPC: summary of product characteristics.
Note: A vaccinee with multiple occurrences of an adverse reaction is counted only once under the applicable system organ class/preferred 
term.
a Only not solicited adverse reactions in the northern hemisphere 2014/15 clinical trial and reported in this ESS are compared with the SmPC 
and included in this table.
b Very common (≥ 1/10 or ≥ 10%); common (≥ 1/100 to < 1/10 or ≥ 1% to < 10%); uncommon (≥ 1/1,000 to < 1/100 or ≥ 0.1% to < 1%); rare (≥ 1/10,000 
to < 1/1,000 or ≥ 0.01% to < 0.1%); very rare (< 1/10,000 or < 0.01%).
c Combined age groups of adult and elderly vaccinees.
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clinical study [11]. No safety issues were observed, and 
the safety profile of the two vaccines was consistent 
with what is known for both products. Per EMA interim 
guidance, data was to be generated from at least two 
batches of the vaccines. This requirement was fulfilled 
for Vaxigrip but was not feasible for Intanza 15 µg 
owing to the fragmented market share.
The passive ESS had the following potential limitations: 
firstly, there was no control over the actual reporting 
(under-reporting was still possible) or the timing of a 
suspected AR report relative to the time since vaccina-
tion (suspected ARs that occurred within 7 days could 
still be reported outside the ESS period). Secondly, the 
age groups in which the vaccine was used could not 
be controlled and depended on national recommen-
dations for influenza vaccination, as well as the vac-
cine coverage rates per age group observed in routine 
practice. In addition, the choice to conduct the ESS in 
two countries, with Finland dedicated to the distribu-
tion of paediatric SRCs, affected the age group dis-
tribution for the SRC. During the ESS, all age groups 
were represented. However, for Vaxigrip, most of the 
SRCs were distributed in the age groups 6 months to 
< 6 years (n = 496) and in the age group older than 65 
years (n = 237). Only 19 SRCs were distributed in the age 
group 13 to 18 years. Therefore, data from this specific 
paediatric age group were difficult to capture owing to 
low influenza vaccine coverage. Thirdly, some degree 
of selection bias may have occurred because vaccinees 
who accepted the SRC might have reported more (or 
fewer) ARs than those who refused the SRC. Moreover, 
HCPs could have preselected the vaccinees to whom 
the SRC was proposed, even if the instructions were to 
distribute the SRC on an ongoing basis to all eligible 
vaccinees. In addition, the vaccinees who received the 
vaccine early in the season might have been different 
from those who received the vaccine later in the sea-
son. However, this bias is most probably limited, as 
some sites distributed the SRCs very quickly to large 
vaccinee groups on days of massive organised influ-
enza vaccinations.
Finally, some operational constraints were faced before 
initiating this ESS at the site level. In the UK, there was 
no official start date and influenza vaccination started 
by the middle of October in the context of ESS at the 
selected sites. In Finland, the national official start date 
for the influenza vaccination was 9 November 2015. 
The start date at the site level for the ESS depended on 
HCP availability for initiation, contract signature, local 
practice organisation for seasonal influenza vaccina-
tion and different local approval dates. The first site 
in Finland started SRC distribution on 10 November 
2015, immediately after the official national start date 
for influenza vaccination. The ESS started as closely as 
possible to the time of the first influenza vaccinations 
in the selected sites in both countries; however, these 
start dates may have been some weeks after the first 
administration of Vaxigrip doses elsewhere in Europe 
and may have affected the speed at which potential 
safety issues could have been detected.
The estimated AR reporting rates will provide base-
line AR reporting rates to improve comparison during 
the next NH influenza season (2016/17) using a simi-
lar passive methodology. A limitation in the current 
comparison is that the reference data from ESS NH 
2014/15 were obtained from active safety surveillance 
(clinical trial) and not from spontaneous reporting. The 
finalisation of the guidance related to ESS is currently 
under discussion at EMA, and current passive ESS pilot 
experiences will provide data to further support recom-
mendations. Despite the historic success of immunisa-
tion in reducing the morbidity and mortality of several 
diseases, some public concerns about the safety of 
vaccines remain. These concerns occasionally erode 
public confidence in immunisation and sometimes lead 
to vaccine hesitancy and disease outbreaks. Therefore, 
enhanced influenza vaccine safety monitoring can con-
tribute to increase public confidence in vaccine safety.
In the absence of a more systemic, centralised, pan-
European safety surveillance system, we believe that 
the passive ESS experience presents a suitable model 
for enhanced passive surveillance of seasonal influ-
enza vaccines.
Conclusions
The current pilot ESS used a passive approach and 
showed higher AR reporting rates than previously 
shown for routine spontaneous reporting. There was 
no obvious distribution pattern in the type and fre-
quency of suspected ARs for Vaxigrip or Intanza 15 µg. 
We did not observe any clinically significant changes 
compared with what is known or expected for either 
vaccine, nor any safety concerns during the current ESS 
period. The ESS results have improved data reporting 
and demonstrated its suitability to health authorities’ 
requirements; further fine tuning of the methodology 
is under discussion between all stakeholders. A con-
tinuous dialogue between the MAHs (through Vaccines 
Europe) and the European health authorities will 
help optimise and scale up the ESS system for future 
seasons.
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